UCB is investing more than £1 billion ($1.29 billion) over five years to expand the company’s research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.

In anticipation of data from a Phase III vaccine candidate study potentially becoming available in October, Germany’s BioNTech acquired a manufacturing facility from Novartis to boost production capabilities for the preventative treatment for the novel coronavirus.

Takeda Pharmaceutical opened a new 24,000-square-foot R&D cell therapy manufacturing facility in Boston at the site of the company’s R&D headquarters.

GlaxoSmithKline opened a new $13 million research hub in London focused on artificial intelligence.

Pfizer Inc. signed a multi-year agreement to make Gilead Sciences Inc.’s antiviral drug remdesivir in a bid to ramp up supply of the Covid-19 treatment.

Tesla, the electric car company founded and run by Elon Musk, is building mobile molecular printers to assist Germany’s CureVac in manufacturing an experimental COVID-19 vaccine.

Amidst the pandemic, the biopharma industry continues to surge ahead as BioSpace reviews companies that have made recent job announcement expansions.

Inovio Pharmaceuticals was one of the earlier companies to identify a potential vaccine candidate against COVID-19, but has run into manufacturing problems that have stymied its development plans.

Vancouver, British Columbia-based AbCellera closed a Series B financing worth $105 million, led by OrbiMed and DCVC Bio.

Contract drug manufacturer Lonza still expects to supply drugmaker Moderna with active ingredients for the company’s experimental COVID-19 vaccine by June or July to support laboratory trials, the Swiss company’s interim CEO, Albert Baehny, told CNBC.